Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen.

@article{Castellon2004NeurocognitivePI,
  title={Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen.},
  author={Steven A. Castellon and Patricia A. Ganz and Julienne E. Bower and Laura Petersen and Laura Abraham and Gail A Greendale},
  journal={Journal of clinical and experimental neuropsychology},
  year={2004},
  volume={26 7},
  pages={955-69}
}
The primary aim of the current study was to examine whether neurocognitive functioning among breast cancer survivors (BCS) exposed to systemic adjuvant chemotherapy differs from that seen among BCS who did not receive chemotherapy. The performance of each of these BCS groups was compared to a demographically matched comparison group without history of breast cancer, a group not included in the majority of previous cognitive functioning studies. We also sought to explore whether usage of the… CONTINUE READING
Highly Influential
This paper has highly influenced a number of papers. REVIEW HIGHLY INFLUENTIAL CITATIONS

9 Figures & Tables

Connections & Topics

Mentioned Connections BETA
EstrogensContraindicated with diseaseMammary Neoplasms
We also sought to explore whether usage of the anti - estrogen drug tamoxifen , a common component of breast cancer treatment , was related to neurocognitive functioning .
Those BCS who received adjuvant chemotherapy performed significantly worse in the domains of verbal learning , visuospatial functioning , and visual memory than BCS treated with surgery only .
Those BCS who received adjuvant chemotherapy performed significantly worse in the domains of verbal learning , visuospatial functioning , and visual memory than BCS treated with surgery only .
Those BCS who received adjuvant chemotherapy performed significantly worse in the domains of verbal learning , visuospatial functioning , and visual memory than BCS treated with surgery only .
Those BCS who received adjuvant chemotherapy performed significantly worse in the domains of verbal learning , visuospatial functioning , and visual memory than BCS treated with surgery only .
We also sought to explore whether usage of the anti - estrogen drug tamoxifen , a common component of breast cancer treatment , was related to neurocognitive functioning .
We also sought to explore whether usage of the anti - estrogen drug tamoxifen , a common component of breast cancer treatment , was related to neurocognitive functioning .
Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen .
Although patients who received chemotherapy ( with and without tamoxifen ) performed worse than those treated with surgery only on several domains , neither group was significantly different from demographically matched comparison subjects without a history of breast cancer .
All Topics